<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65432">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01890538</url>
  </required_header>
  <id_info>
    <org_study_id>KOU KAEK 2013/174</org_study_id>
    <nct_id>NCT01890538</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo</brief_title>
  <official_title>Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kocaeli University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kocaeli University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate
      and piracetam) in the symptomatic management of peripheral vertigo.

      The patients will be randomized in two groups according to symptomatic treatment modalities:
      Dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30
      minutes. Each patient will be asked if her/his vertigo symptoms resolved or not, according
      to a numeric rating scale (0=no vertigo, 10=worst possible vertigo). The patient will be
      rate the intensity of symptoms in the following times:

        -  Numeric rating scale (1 to 10): Admission

        -  Numeric rating scale (1 to 10): After the study drug (No ambulation)*

        -  Numeric rating scale (1 to 10): After the study drug (Ambulation)*

             -  Ambulation refers to head movements or walking in the room, if applicable.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in numeric rating scale</measure>
    <time_frame>Change from baseline in numeric rating scale at 30th minute</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Peripheral Vertigo</condition>
  <arm_group>
    <arm_group_label>Piracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 g intravenous piracetam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dimenhydrinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dimenhydrinate 100 mg intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of 100 mg dimenhydrinate intravenous</intervention_name>
    <arm_group_label>Dimenhydrinate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 g piracetam intravenous</intervention_name>
    <arm_group_label>Piracetam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting to emergency department with vertigo symptoms

          -  Adult patients (over 18)

          -  Agree to participate to study (understanding the study protocol and signing the
             informed consent form)

        Exclusion Criteria:

          -  Patients under 18 years

          -  Patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging

          -  Patient diagnosed with transient ischemic attack

          -  Pregnants

          -  Patients taking any analgesics or antihistaminic drugs last 24 hours

          -  Documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines

          -  Patients who do not agree to participate to the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nurettin Özgür Doğan, M.D., Assistant Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kocaeli University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kocaeli University</name>
      <address>
        <city>Kocaeli</city>
        <zip>41000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=11020677</url>
  </link>
  <reference>
    <citation>Scholtz AW, Schwarz M, Baumann W, Kleinfeldt D, Scholtz HJ. Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study. Clin Ther. 2004 Jun;26(6):866-77.</citation>
    <PMID>15262457</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kocaeli University</investigator_affiliation>
    <investigator_full_name>Nurettin Özgür Doğan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>vertigo</keyword>
  <keyword>dimenhydrinate</keyword>
  <keyword>piracetam</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vertigo</mesh_term>
    <mesh_term>Dizziness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dimenhydrinate</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
